Non-coding RNAs enhance the apoptosis efficacy of therapeutic agents used for the treatment of glioblastoma multiform.
Glioblastoma multiform
apoptosis
long non-coding RNAs
microRNAs
temozolomide
Journal
Journal of drug targeting
ISSN: 1029-2330
Titre abrégé: J Drug Target
Pays: England
ID NLM: 9312476
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
pubmed:
15
3
2022
medline:
16
6
2022
entrez:
14
3
2022
Statut:
ppublish
Résumé
The treatment of brain tumours remains a challenge despite progress in surgical techniques and radio/chemotherapy. The therapeutic outcomes for glioblastoma multiform (GBM) have not been satisfactory and result in median overall survival (12-18 months). GBM displays both intra- and inter-tumour heterogeneity, causing resistance and eventually tumour recurrence. In this review, we address molecular events responsible for the dysregulation of apoptosis and introduce newly discovered non-coding RNAs (MicroRNAs and Long non-coding RNAs) that regulate tumour growth and enhance therapeutic outcomes in GBM. The combinatory use of MicroRNAs and Long non-coding RNAs with chemotherapeutic compounds, as well as the induction of suicide genes, provide an innovative therapeutic approach for the management of GBM. The understanding of GBM pathogenesis, intrinsic drug resistance mechanism, and targetable oncogenic pathways could lead to establishing novel approaches and techniques to combat GBM.
Identifiants
pubmed: 35282758
doi: 10.1080/1061186X.2022.2047191
doi:
Substances chimiques
MicroRNAs
0
RNA, Long Noncoding
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM